p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma

Journal of Urology

Volumn 155, Issue 5, 1996, Pages 1685-1692

  Prendergast, Neal J ^a   Atkins, Mark R ^a   Schatte, Edward C ^a   Paulson, David F ^a   Walther, Philip J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

genes, p53; immunohistochemistry, treatment outcome; prostatic neoplasms; radiotherapy

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; STATISTICAL ANALYSIS;

EID: 0029868812     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66165-2     Document Type: Article

References (29)

1. Sklar, G. N., Eddy, H. A., Jacobs, S. C. and Kyprianou, N.: Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J. Urol., 150: 1526, 1993.
2. Wyllie, A. H.: Apoptosis (the 1992 Frank Rose Memorial Lecture). Brit. J. Cancer, 67: 205, 1993.
3. Lee, J. M. and Bernstein, A.: p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci., 90: 5742, 1993.
4. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I. and Kohn, K. W.: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776, 1993.
5. Levine, A. J., Perry, M. E., Chang, A., Silver, A., Dittmer, D., Wu, M. and Welsh, D.: The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Brit. J. Cancer, 69: 409, 1994.
6. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. and Jacks, T.: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362: 847, 1993.
7. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C.: p53 mutations in human cancers. Science, 253: 49, 1991.
8. Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B. and Levine, A. J.: Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ., 1: 571, 1990.
9. Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke-Pearson, D. L., Iglehart, J. D., Bast, R. C., Jr. and Berchuck, A.: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51: 2979, 1991.
10. Cordon-Cardo, C., Dalbagni, G., Saez, G. T., Oliva, M. R., Zhang, Z. F., Rosai, J., Reuter, V. E. and Pellicer, A.: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer, 56: 347, 1994.
11. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C. and Conti, C. J.: p53 Protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657, 1993.
12. Effert, P. J., McCoy, R. H., Walther, P. J. and Liu, E. T.: p53 gene alterations in human prostate carcinoma. J. Urol., 150: 257, 1993.
13. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F. and Allred, D. C.: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53: 3369, 1993.
14. Visakorpi, T., Kallionieni, O.-P., Heikkinen, A., Koivula, T. and Isola, J.: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst., 84: 883, 1992.
15. Voeller, H. J., Sugars, L. Y., Pretlow, T. and Gelmann, E. P.: p53 oncogene mutations in human prostate cancer specimens. J. Urol., 151: 492, 1994.
16. Aprikian, A. G., Sarkis, A. S., Fair, W. R., Zhang, Z.-F., Fuks, Z. and Cordon-Cardo, C.: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol., 151: 1276, 1994.
17. Chi, S. G., deVere White, R. W., Meyers, F. J., Siders, D. B., Lee, F. and Gumerlock, P. H.: p53 in prostate cancer: frequent expressed transition mutations. J. Natl. Cancer Inst., 86: 926, 1994.
18. Scardino, P. T., Frankel, J. M., Wheeler, T. M., Meacham, R. B., Hoffman, G. S., Seale, C., Wilbanks, J. H., Easley, J. and Carlton, C. E., Jr.: The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J. Urol., 135: 510, 1986.
19. Moul, J. W. and Paulson, D. F.: The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer, 68: 1265, 1991.
20. Neerhut, G. J., Wheeler, T., Cantini, M. and Scardino, P. T.: Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J. Urol., 140: 544, 1988.
21. Gleason, D. F.: Classification of prostate carcinomas. Cancer Chemother. Rep., part 1, 50: 125, 1966.
22. Sarkar, F. H., Li, Y. W. and Crissman, J. D.: A method for PCR sequencing of the p53 gene from a single 10-microns frozen or paraffin-embedded tissue section. Biotechniques, 15:36, 1993.
23. Effert, P. J., Neubauer, A., Walther, P. J. and Liu, E. T.: Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J. Urol., 147: 789, 1992.
24. Orita, M., Suzuki, Y., Sekiya, T. and Hayashi, K.: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5:874, 1989.
25. De la Calle-Martin, O., Fabregat, V., Romero, M., Soler, J., Vives, J. and Yague, J.: Acc II polymorphism of the p53 gene. Nucl. Acids Res., 18: 4963, 1990.
26. Kerns, B. J., Jordan, P. A., Moore, M. B., Humphrey, P. A., Berchuck, A., Kohler, M. F., Bast, R. C., Jr., Iglehart, J. D. and Marks, J. R.: p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J. Histochem. Cytochem., 40: 1047, 1992.
27. Collet, D.: Modelling Binary Data. London: Chapman & Hall, 1991.
28. Isaacs, W. B., Carter, B. S. and Ewing, C. M.: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 51: 4716, 1991.
29. Schatte, E., Prendergast, N. J. and Walther, P. J.: High incidence of p53 mutations in locally recurrent/persistent prostate cancer following radiation therapy. Proc. Amer. Ass. Cancer Res., 35: 642, 1994.